This document provides an open forum for group discussion, comments, and Q&A on quality by design (QbD) approaches for pharmaceutical manufacturing. It poses 12 yes or no questions about key aspects of QbD, including whether a design space or real time release testing is required, whether all parameter interactions must be studied, and whether a site change invalidates a design space. The forum is intended to facilitate an exciting discussion on the regulatory acceptance of traditional versus QbD approaches.